Issue 7, 2022

The Mössbauer effect using 57Fe-ferrabisdicarbollide ([o-57FESAN]): a glance into the potential of a low-dose approach for glioblastoma radiotherapy

Abstract

Although a variety of cancers are initially susceptible to chemotherapy, they eventually develop multi-drug resistance. To overcome this situation, more effective and selective treatments are necessary using anti-tumour agents that act in two or more ways and offer greater therapeutic benefits over single-mechanism entities. In this study, we report on treating cancer with Na[3,3′-57Fe(1,2-C2B9H11)2], which offers the possibility of dual action (radiation–drug combinations) to improve the clinical benefits and reduce healthy tissue toxicity. An approach to evaluating the potential of [o-57FESAN] to treat glioblastoma using the Mössbauer effect is presented. As the therapeutic outcomes rely on the amount and distribution of [o-57FESAN] inside the cells, several studies, using magnetization, Mössbauer spectroscopy and nuclear microscopy techniques, were performed to ascertain the uptake of [o-57FESAN] in U87 glioblastoma cells. [o-57FESAN] was found to be within the cells; 29% of its uptake was in the nuclear fraction, which is a particularly desirable target, because the nucleus is the cell's control centre where DNA and the transcription machinery reside. Irradiation studies with 2D and 3D cellular models of U87 cells showed that the growth inhibition effect observed was more pronounced when [o-57FESAN] was used in combination with the Mössbauer effect in low total dose regimens, suggesting that this procedure either alone or as adjuvant may be useful for glioblastoma treatment.

Graphical abstract: The Mössbauer effect using 57Fe-ferrabisdicarbollide ([o-57FESAN]−): a glance into the potential of a low-dose approach for glioblastoma radiotherapy

Supplementary files

Article information

Article type
Research Article
Submitted
06 Dec 2021
Accepted
01 Feb 2022
First published
04 Feb 2022
This article is Open Access
Creative Commons BY-NC license

Inorg. Chem. Front., 2022,9, 1490-1503

The Mössbauer effect using 57Fe-ferrabisdicarbollide ([o-57FESAN]): a glance into the potential of a low-dose approach for glioblastoma radiotherapy

A. B. Buades, L. C. J. Pereira, B. J. C. Vieira, A. C. Cerdeira, J. C. Waerenborgh, T. Pinheiro, A. P. A. Matos, C. G. Pinto, J. F. Guerreiro, F. Mendes, S. Valic, F. Teixidor, C. Viñas and F. Marques, Inorg. Chem. Front., 2022, 9, 1490 DOI: 10.1039/D1QI01513C

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements